UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
(Exact name of registrant as specified in its charter)
|
|
|
(State or other jurisdiction of incorporation or organization) |
(Commission File Number) |
(I.R.S. Employer Identification No.) |
(
(Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices)
N/A
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Exchange Act:
Title of Each Class |
Trading Symbol |
Name of Each Exchange on Which Registered |
|
|
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company |
|
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
On January 6, 2022, Odonate Therapeutics, Inc. (the “Company”) received written notice from The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that Nasdaq believes that the Company is a "public shell" pursuant to Listing Rule 5101, and that the continued listing of its securities is no longer warranted. The Company will not appeal this determination. Therefore, the Company expects the trading of its common stock on The Nasdaq Stock Market to be suspended at the opening of business on January 18, 2022, and that Nasdaq will file a Form 25-NSE with the U.S. Securities and Exchange Commission (the “SEC”), which will remove the Company’s securities from listing and registration on The Nasdaq Stock Market. Additionally, the Company intends to file with the SEC a Form 15 requesting the suspension of the Company’s reporting obligations.
Item 9.01 Financial Statements and Exhibits
(d) Exhibits
Exhibit No. |
|
Description |
|
|
|
104 |
|
Cover Page Interactive Data File (embedded within the Inline XBRL document) |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
Odonate Therapeutics, Inc. |
||
|
|
|
|
Date: January 7, 2022 |
By: |
|
/s/ Michael Hearne |
|
|
|
Michael Hearne |
|
|
|
Chief Financial Officer |
Document and Entity Information |
Jan. 06, 2022 |
---|---|
Cover [Abstract] | |
Document Type | 8-K |
Amendment Flag | false |
Document Period End Date | Jan. 06, 2022 |
Entity Registrant Name | Odonate Therapeutics, Inc. |
Entity Central Index Key | 0001717452 |
Entity Incorporation State Country Code | DE |
Entity File Number | 001-38318 |
Entity Tax Identification Number | 82-2493065 |
Entity Address, Address Line One | 3 East 28th Street |
Entity Address, Address Line Two | 10th Floor |
Entity Address City Or Town | New York |
Entity Address State Or Province | NY |
Entity Address Postal Zip Code | 10016 |
City Area Code | 332 |
Local Phone Number | 206-0935 |
Written Communications | false |
Soliciting Material | false |
Pre Commencement Tender Offer | false |
Pre Commencement Issuer Tender Offer | false |
Security12b Title | Common Stock, $0.01 par value per share |
Trading Symbol | ODT |
Security Exchange Name | NASDAQ |
Entity Emerging Growth Company | true |
Entity Ex Transition Period | true |
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end
(['G&FW6)\9@T$8#)TM;XQ)R;M>".I)C+P5?_(UP3"'!:,.IMJD
M6);<2R@7'A %B!^UD+:(SM:QL6':SY.0FIN GTA5*NW_.H HE[]/5$4EZ%9M+>]NT)[
M9D9#&[+?LE5%-#:QG@XH+U.[:N^"RB7 3L) -88RU*
M&6TQ?5BOM?0&K=9:K4'5,FI-H][0[>Q*/7\J^,TH(#O6KEHBX.NZS''8E)QR
ME[H6IP[I)YCN 6DLC1P[#KG";I)<,28:!8K@D<%?7A6J=JNJ5 S#OQ!1XH_/U;42\TR]3"&E%).3W-7!5?[K/4
M#DO9R^-:YWIEG0+;X04SY@&2*-I5VK]A\U/!MJIDG>SKE]7"BIM8XS^@$59K
M"1K>PG%A1^O[UEGAI[%VML!?T@#%LW\WYV:!;5/(-L5)=;'W>R^8#KS$;:")
M&NS0@/$)X]&^<#>4-7_!IC*"^04;E"S)+5!U_)(+O;."3;&"B!8DO$ 1VU+!
MQ7+(2@IJ>;Z(H529**)K3-#M=-Q'O%S%K/:K(_<29V>UH"A S&&+[36JLSQ5
M;%*8E!?7A%%[<-89R DW'\26 5UV:"U!$X W1G?I9\($UHF;NWI8H55L_:
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M4A1U:T;G:H)JPS<_$6RK1M:)3JKI7<_.749P@$-,1U_E>IMC
M2(IZ6=>SFJ:;2.9=O.0 "Y+]6SA'?)8OC5U"DPH:U[/M/4>J/I"4-_H"L7J^
MA-\-A\47#GD(U=3-1C1O9\D%5LE S 8BNOT;NT!Z6#'1[$P%J94%H];O"#%%
MO'X!:'",:+^!^PK%$'/:71/9>=-71H:.-NN)%'ZN?2
MDE,X_@FQL_\!4$L#!!0 ( !%()U2SX&SX( 4 -8N 4 ;V1T+3(P
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MJN=4?W64^H5]L*&@BPQ\D5^\9)9VX]U5L$5U
M2$%%,&M-:5/1#"(H[% $RJT9:^%6;BDNY98L!E5-.6!V;XV*8;$E!VH'XA&*
M.0& Y@HV8Q\=EY[IR7CQ'-"0F\(*A0#EGA9#)ZWY+E[H!F)6CZ@QC[$;CLTB
MD31UP#E@KN0#AY41C FE]+)LHM6)11KLR&V. I.J&L!HM]L5U9I*7"!FZDJ[
M JT)X),A\UJ%S0,J4ZWBTJN91G.>'D80Z9HE+UHQ@!J5/[Y_ZULC-J;EQ\K+
M[V?-8*"FHSU%